fbpx

Day

oktober 12, 2015
NEW YORK, Oct. 9, 2015 /PRNewswire-iReach/ -- River Vision Development Corp. (RVDC) today announced the completion of enrollment of a Phase 2 clinical study of RV001 (teprotumumab) for the treatment of Graves' Orbitopathy (GO). RV001 is a fully human IGF-1 receptor antagonist antibody with a safety database comprised of more than 700 cancer patients. The study is being conducted at 15 sites...

Nyheder

Lundbeckfonden øger sit engagement i IO Biotech
12. januar 2021
Lundbeckfonden lancerer 2030-strategi med ambitiøse mål for både uddelings- og erhvervsaktiviteterne
22. december 2020
Lundbeckfonden uddeler 57 mio. kr. til dristige projekter
15. december 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge